References
- Riaz MH, Barrington C, Ionescu A. A minimalist cardio-oncology service: A personal experience from Wales. Romanian Journal of Cardiology. 2024;34(4):161-164. https://doi.org/10.2478/rjc-2024-0018
- Ainger LE, Bushore J, Johnson WW, Ito J. Daunomycin: a cardiotoxic agent. J Natl Med Assoc. 1971;63(4):261–7.
- Ali MK, Kahlil KG, Fuller LM, et al. Radiation-related myocardial injury. Management of two cases. Cancer. 1976;38(5):1941–6.
- Henderson IC, Sloss LJ, Jaffe N, Blum RH, Frei E 3rd. Serial studies of cardiac function in patients receiving adriamycin. Cancer Treat Rep. 1978;62(6):923–9.
- Cardinale D. [A new frontier: cardio-oncology]. Cardiologia. 1996;41(9):887–91.
- Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–16.
- Yeh ET. Onco-cardiology: the time has come. Tex Heart Inst J. 2011;38(3):246–7.
- Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J. 2011;38(3):259–60.
- Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 2010;53(2):88–93.
- Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors: A roadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739–46.
- Iliescu CA, Grines CL, Herrmann J, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2016;87(5):E202–23.
- Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.
- Lopez-Mattei J, Yang EH, Baldassarre LA, et al. Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). J Cardiovasc Comput Tomogr. 2023;17(1):66–83.
- Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443–50.
- Wilson NR, Lee MT, Gill CD, et al. Prognostic factors and overall survival after pericardiocentesis in patients with cancer and thrombocytopenia. Front Cardiovasc Med. 2021;8:638943.
- Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J. 2010;37(3):336–40.
- Schechter M, Balanescu DV, Donisan T, et al. An update on the management and outcomes of cancer patients with severe aortic stenosis. Catheter Cardiovasc Interv. 2019;94(3):438–45.
- Yusuf SW, Sarfaraz A, Durand JB, Swafford J, Daher IN. Management and outcomes of severe aortic stenosis in cancer patients. Am Heart J. 2011;161(6):1125–32.
- Balanescu SM, Balanescu DV, Donisan T, et al. The onco-cardiologist dilemma: To implant, to defer, or to avoid transcatheter aortic valve replacement in cancer patients with aortic stenosis? Curr Cardiol Rep. 2019;21(8):83.
- Gill C, Lee M, Balanescu DV, et al. Transcatheter and surgical aortic valve replacement impact on outcomes and cancer treatment schedule. Int J Cardiol. 2021;326:62–70.
- Thomason N, Monlezun DJ, Javaid A, et al. Percutaneous coronary intervention in patients with gynecological cancer: Machine learning-augmented propensity score mortality and cost analysis for 383,760 patients. Front Cardiovasc Med. 2021;8:793877.
- Marmagkiolis K, Monlezun DJ, Caballero J, et al. Prevalence, mortality, cost, and disparities in transcatheter mitral valve repair and replacement in cancer patients: Artificial intelligence and propensity score national 5-year analysis of 7495 procedures. Int J Cardiol. 2024;408:132091.
- Pushparaji B, Donisan T, Balanescu DV, et al. Interventional strategies in cancer-induced cardiovascular disease. Curr Oncol Rep. 2021;23(11):133.
- Chauhan S, Monlezun DJ, Kim JW, et al. Fractional flow reserve cardio-oncology effects on inpatient mortality, length of stay, and cost based on malignancy type: Machine learning supported nationally representative casecontrol study of 30 million hospitalizations. Medicina (Kaunas). 2022;58(7).
- Kim JW, Dayah TJ, Javaid A, et al. Reclassification of treatment strategy with fractional flow reserve in cancer patients with coronary artery disease. Medicina (Kaunas). 2022;58(7).
- Iliescu CA, Cilingiroglu M, Giza DE, et al. “Bringing on the light” in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017;194:83–91.
- Honan KA, Hassan S, Deswal A, et al. Bioprosthetic valve monitoring in patients with carcinoid heart disease. Front Cardiovasc Med. 2022;9:1072890.
- Monlezun DJ, Badalamenti A, Javaid A, et al. Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the “forgotten pulmonic valve”. Front Cardiovasc Med. 2022;9:1071138.
- Ahmed T, Marmagkiolis K, Ploch M, et al. The year in cardio-oncology 2022. Curr Probl Cardiol. 2023;48(1):101435.